Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promedior Inc.

This article was originally published in Start Up

Executive Summary

In normal healing, monocytes differentiate into both regulatory macrophages and profibrotic cells known as M2 macrophages and fibrocytes. During fibrosis, that balance is upset and differentiation favors profibrotic cells. Promedior Inc. is developing pentraxin therapeutics designed to control the initiation and progression of fibrosis across a variety of tissues and organ systems.

You may also be interested in...



Start-Up Previews

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.

Homology Medicines Inc.

Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.

X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel